Leonard G. Gomella, MD, from the Kimmel Cancer Center, discusses the utilization of circulating tumor cells in patients with solid tumors.
Leonard G. Gomella, MD, Chair of Urology at Thomas Jefferson University Hospital and Director of Clinical Affairs at the Kimmel Cancer Center, discusses the utilization of circulating tumor cells (CTCs) in patients with solid tumors.
A major challenge currently facing the use of CTCs is a lack of adequate assays to accurately detect low levels of cells. However, Gomella adds, techniques and gradient technologies are currently being assessed to alleviate sensitivity concerns with very low cell counts.
An exciting area of research involves capturing CTC and interrogating them for genetic alterations, Gomella notes. In the future, this area of research will continue to be explored further.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More